Education
About Us
Working with TipRanks
Follow Us
Airsculpt Technologies, Inc. (AIRS)
NASDAQ:AIRS
Top Page
Airsculpt Technologies
(NASDAQ:AIRS)
54Neutral
Positive Factors
Capital Deployment
De novos absolutely remain the best way to deploy capital with 100% ROIC in year one.
Liquidity Support
The company announced a $100 million ATM equity financing as a liquidity backstop.
Operational Strategy
New leadership intends to turn back on marketing spend and use techniques that have historically produced results, such as online videos and other social channels.
Negative Factors
Earnings Expectations
The full-year EBITDA has been lowered primarily due to a slower ramp of new centers, which impacts earnings contribution.
Financial Performance
AIRS previewed very disappointing 4Q24 results, missing EBITDA expectations by 70% and coming in well below the company's full-year guidance range.
Revenue Pressure
Volume remains under a good deal of pressure, with SS revenue growth continuing to decline to historically low levels.
Airsculpt Technologies (AIRS) vs. S&P 500 (SPY)
Market Cap
$134.90M
Dividend YieldN/A
Average Volume (3M)406.43K
Price to Earnings (P/E)―
Beta (1Y)2.33
Revenue Growth-12.96%
EPS Growth-1199.26%
CountryUS
Employees389
SectorHealthcare
Sector Strength46
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding58,779,850
10 Day Avg. Volume595,553
30 Day Avg. Volume406,427
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.16
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside-16.39% Downside
Rating ConsensusHold
Number of Analyst Covering1
Airsculpt Technologies Business Overview & Revenue Model
Company DescriptionAirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
How the Company Makes MoneyAirsculpt Technologies, Inc. generates revenue primarily through the provision of its AirSculpt® body contouring services. Clients pay for these cosmetic procedures, which are performed in the company's specialized clinics. Revenue is driven by the demand for elective cosmetic surgeries, with pricing based on the specific areas treated and the extent of the procedure. The company may also benefit from repeat business or referrals from satisfied clients. While partnerships and collaborations with other medical or cosmetic institutions could play a role, the company's main earnings are derived from direct consumer sales of its services.
Airsculpt Technologies Financial Statement Overview
Summary
Airsculpt Technologies faces financial pressures with declining revenue and profitability, coupled with high leverage. The company's ability to generate cash flow remains a concern, emphasizing the need for strategic adjustments to improve financial health.Income Statement
Airsculpt Technologies has shown a volatile revenue trajectory with a recent decline in revenue and profitability. The gross profit margin remains high, but negative EBIT and a declining net profit margin indicate operational challenges.60
Neutral
Balance Sheet
The company's balance sheet reflects high leverage with a substantial debt-to-equity ratio, raising concerns about financial stability. The equity ratio has decreased, indicating increased reliance on debt financing.50
Neutral
Cash Flow
Cash flow from operations is positive, but free cash flow is negative, suggesting that capital expenditures are impacting liquidity. A declining operating cash flow to net income ratio highlights potential efficiency issues.55
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 180.35M | 195.92M | 168.79M | 133.31M | 62.77M | Gross Profit |
| 108.97M | 121.91M | 106.01M | 88.78M | 39.30M | EBIT |
| -1.82M | 9.48M | -3.47M | 15.77M | 10.03M | EBITDA |
| 10.07M | 19.74M | 3.52M | 23.05M | 15.67M | Net Income Common Stockholders |
| -8.25M | -4.48M | -14.68M | 10.55M | 5.75M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 8.23M | 10.26M | 9.62M | 25.35M | 10.38M | Total Assets |
| 210.00M | 204.02M | 200.76M | 200.55M | 179.61M | Total Debt |
| 105.05M | 99.67M | 107.65M | 100.58M | 49.77M | Net Debt |
| 96.82M | 89.41M | 98.03M | 75.24M | 39.39M | Total Liabilities |
| 130.71M | 120.03M | 129.99M | 117.03M | 55.93M | Stockholders Equity |
| 79.29M | 83.99M | 70.77M | 83.53M | 123.68M |
| Cash Flow | Free Cash Flow | |||
| -2.66M | 14.04M | 11.53M | 19.52M | 10.27M | Operating Cash Flow |
| 11.35M | 23.96M | 24.45M | 26.63M | 13.96M | Investing Cash Flow |
| -14.01M | -9.92M | -12.92M | -7.12M | -3.69M | Financing Cash Flow |
| 630.00K | -13.39M | -27.26M | -4.55M | -5.02M |
Airsculpt Technologies Technical Analysis
Positive
2.99
Price Trends
2.52
Positive
3.95
Negative
4.65
Negative
Market Momentum
0.08
Negative
62.18
Neutral
73.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Positive. The current price of 2.99 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 2.52, and below the 200-day MA of 4.65, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 62.18 is Neutral, neither overbought nor oversold. The STOCH value of 73.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIRS.
Airsculpt Technologies Risk Analysis
Airsculpt Technologies disclosed 74 risk factors in its most recent earnings report. Airsculpt Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Airsculpt Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.47B | 14.40 | 11.19% | 2.43% | 19.16% | 31.92% | |
68 Neutral | $3.12B | 35.27 | 7.85% | ― | 5.34% | ― | |
67 Neutral | $1.09B | 39.24 | 6.72% | 2.39% | 14.30% | 76.89% | |
63 Neutral | $2.95B | ― | -8.90% | ― | 13.52% | -1296.44% | |
54 Neutral | $134.90M | ― | -21.30% | ― | -12.96% | -1199.26% | |
53 Neutral | $150.93M | ― | -27.25% | ― | -26.14% | 23.04% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.53% |
* Healthcare Sector Average
Performance Comparison
AIRS
Airsculpt Technologies
2.99
-1.68
-35.97%
AMED
Amedisys
95.31
-0.09
-0.09%
NHC
National Healthcare
100.54
5.80
6.12%
USPH
US Physical Therapy
74.07
-28.79
-27.99%
JYNT
Joint
9.99
-6.46
-39.27%
SGRY
Surgery Partners
22.16
-3.72
-14.37%
Airsculpt Technologies Earnings Call Summary
Earnings Call Date:May 02, 2025
(Q1-2025)
| % Change Since: 32.30%|
Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted several strategic initiatives showing early success, such as cost discipline and lead generation improvements. However, significant challenges remain, including a notable revenue decline and a challenging consumer environment affecting sales. While strategic efforts are promising, current financial metrics reflect ongoing headwinds.Q1-2025 Updates
Positive Updates
Successful Strategic Initiatives
AirSculpt Technologies reported early traction in key strategic initiatives, including cost discipline, marketing efficiency, and operational rigor, resulting in $1.9 million more in adjusted EBITDA versus Q4 2024.
Strong Lead Generation
The company achieved strong lead volume growth over Q1 last year by reallocating marketing dollars effectively, driving significant lead growth without increasing spend.
New Service Launch
AirSculpt launched a pilot of its skin tightening procedure to tap into increased demand, representing a potential new revenue stream.
Improved Organizational Strength
New hires, including a Chief Digital Officer and Chief Sales Officer, have strengthened the organization and driven improvements in lead generation and sales processes.
Negative Updates
Revenue Decline
Revenue for the first quarter was $39.4 million, a decline of 17.3% from the first quarter of 2024, driven by lower case volume.
Same-Store Revenue Decrease
Same-store revenue declined approximately 24% over the prior year quarter, consistent with the Q4 trend.
Challenging Macroeconomic Environment
The company continues to operate in a challenging consumer environment, contributing to a decline in case volume and consumer spending softness.
Increased SG&A Expenses
Selling, general, and administrative expenses increased by $6 million in the quarter compared to the same period in fiscal 2024, primarily due to equity-based compensation.
Company Guidance
During the AirSculpt Technologies First Quarter 2025 Earnings Call, guidance was provided regarding the company's financial outlook for the fiscal year. The company expects revenue to be between $160 million and $170 million, with adjusted EBITDA projected to range from $16 million to $18 million. This guidance reflects the current economic conditions and includes a conservative approach due to the uncertain consumer spending environment. The company does not anticipate a downturn in the economy but is preparing for continued pressures on consumer behavior. In the first quarter, revenue was reported at $39.4 million, a decrease of 17.3% from the same period in 2024, while adjusted EBITDA was $3.8 million, representing a margin of 9.5%. The company is focusing on initiatives to improve sales and operational efficiency, including enhanced marketing strategies and expanded financing options, to drive growth despite the challenging environment.Airsculpt Technologies Corporate Events
Executive/Board ChangesShareholder Meetings
Airsculpt Technologies Elects Directors at Annual Meeting
Neutral
May 8, 2025
On May 7, 2025, AirSculpt Technologies held its annual meeting of stockholders where two Class I directors, Yogi Jashnani and Daniel Sollof, were elected for a three-year term. Additionally, Grant Thornton was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, indicating continued stability in the company’s governance and financial oversight.
Spark’s Take on AIRS Stock
According to Spark, TipRanks’ AI Analyst, AIRS is a Neutral.
Airsculpt Technologies is facing notable financial challenges, highlighted by declining revenue and profitability, and high leverage. While strategic initiatives from the earnings call show some promise, the stock’s technical indicators and valuation metrics remain weak. The company needs to address these financial and operational headwinds to improve investor confidence.
To see Spark’s full report on AIRS stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.